Dr. James Howard Jr, MD

• Neurology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Vermont And State Agricultural College

  Medical School, 1974

• Sources of variation in estimates of Duchenne and Becker muscular dystrophy prevalence in the United States, 2023-03-22

• Complement Inhibitor Therapy for Myasthenia Gravis, 2020-06-03

• Effect of Therapeutic Plasma Exchange on Immunoglobulins in Myasthenia Gravis, 2016-08-11

• The economic burden of individuals living with generalized myasthenia gravis and facing social determinants of health challenges, 2023-09-12

• Reduced plasmablast frequency is associated with seronegative myasthenia gravis, 2020-12-24

• Classical Complement Pathway Inhibition in a "Human-On-A-Chip” Model of Autoimmune Demyelinating Neuropathies, 2022-04-05

• Canine Models of Duchenne Muscular Dystrophy and Their Use in Therapeutic Strategies, 2012-01-05

• The Paradox of Muscle Hypertrophy in Muscular Dystrophy, 2016-07-14

• Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study, 2020-11-24

• Learning from the past: reflections on recently completed MG trials, 2017-10-24

• Eculizumab improves fatigue in refractory generalized myasthenia gravis, 2019-03-23

• In VivoViscoelastic Response (VisR) Ultrasound For Characterizing Mechanical Anisotropy in Lower-Limb Skeletal Muscles of Boys With and Without Duchenne Muscular Dystrophy, 2018-08-31

• Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis, 2023-03-09

• Imbalance in T Follicular Helper Cells Producing IL-17 Promotes Pro-inflammatory Responses in MuSK Antibody Positive Myasthenia Gravis, 2020-05-27

• Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension, 2023-04-27

• A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial, 2018-05-10

• Consistent improvement with eculizumab across muscle groups in myasthenia gravis R. Mantegazzaet al., 2020-07-22

• Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE), 2021-07-07

• Racial and ethnic differences in timing of diagnosis and clinical services received in Duchenne Muscular Dystrophy, 2023-01-09

• Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive Myasthenia Gravis patients, 2018-11-22

• ‘Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab, 2020-03-18

• Role attainment in emerging adulthood: subjective evaluation by male adolescents and adults with Duchenne and Becker muscular dystrophy, 2022-05-08

• Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses J. F. Howard Jret al., 2021-05-27

• Divergent effects of T cell costimulation and inflammatory cytokine production on autoimmune peripheral neuropathy provoked by Aire deficiency, 2013-03-13